The chief biosafety expert of the Chinese Center for Disease Control and Prevention (China CDC), Wu GuiZhen, forecasted that the public would have injections of Chinese COVID-19 vaccines as early as November or December, according to the interview with CCTV on September 15. Wu introduced that currently, China accounts for five among a total of nine vaccine candidates that have entered phase III clinical trials worldwide, including four self-developed by domestic companies and one under the collaboration between the country and other nations. Moreover, she said that the National Health Commission (NHC) is arranging experts for the review of coronavirus vaccine production facilities, with two having passed.
Notably, among the five vaccine candidates in the last-stage clinical testing, CanSino Biologics [6185:HK] obtained approval from the Chinese military for one-year use in end-June. In the meantime, the three inactivated COVID-19 vaccines from China National Pharmaceutical Group (AKA Sinopharm) and Sinovac Biotech [SVA:US] also have been put into the emergency use since July 22. The emergency use mainly covers essential groups such as medical and border inspection personnel, as well as state-owned enterprises’ overseas-assigned workers, which might extend to more groups, preparing for the potential epidemic in the upcoming winter, according to Zheng Zhongwei, a director of the NHC. In addition, United Arab Emirates (UAE) foreign ministry spokesman disclosed that the country has approved emergency use of Sinopharm’s inactivated vaccine, which started last-stage clinical trials there from July, on its front-line medical personnel, marking as the first foreign country doing this.